CompletedPhase 3NCT01697267
Rituximab Vasculitis Maintenance Study
Studying Anti-neutrophil cytoplasmic antibody-associated vasculitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Principal Investigator
- David Jayne, MDCambridge University Hospitals NHS Foundation Trust
- Intervention
- Rituximab(biological)
- Enrollment
- 188 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2013 – 2019
Study locations (30)
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Hospital for Special Surgery, New York, New York, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- University of Pennsylvania, Philadelphia, Pennsylvania, United States
- University of Pittsburgh, Pittsburgh, Pennsylvania, United States
- University of Utah, Salt Lake City, Utah, United States
- Canberra Hospital, Garran, Australian Capital Territory, Australia
- Royal Brisbane & Women's Hospital, Herston, Queensland, Australia
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- St. Joseph's Healthcare, Hamilton, Ontario, Canada
- Mount Sinai Hospital, Toronto, Ontario, Canada
- General Faculty Hospital, Prague, Czechia
- +15 more locations on ClinicalTrials.gov
Collaborators
Arthritis Research UK · Roche Pharma AG · Genentech, Inc. · University of Pennsylvania
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01697267 on ClinicalTrials.govOther trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07556484Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeMayo Clinic
- RECRUITINGEARLY PHASE1NCT07507201Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune DiseaseThe Children's Hospital of Zhejiang University School of Medicine
- RECRUITINGNCT07258524PET Assessment of Disease Activity and Cardiovascular Disease Risk in ANCA-associated VasculitisUniversity of Edinburgh
- RECRUITINGPHASE1NCT07315087CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune DiseasesInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07160608Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisAlexion Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT07168161BDB-001 Phase III Trial in ANCA-Associated VasculitisStaidson (Beijing) Biopharmaceuticals Co., Ltd
- RECRUITINGPHASE3NCT06983821Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW)Ottawa Hospital Research Institute
- RECRUITINGNCT07151521(68)Ga-FAPI PET/CT in Patients With ANCA-associated VasculitisRuijin Hospital
See all trials for Anti-neutrophil cytoplasmic antibody-associated vasculitis →